Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01356147 · ClinicalTrials.gov registry record · Phase 4
Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)
A Phase 4 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT01356147 is a Phase 4 study that has completed, run by Georgetown University. The registered enrollment target is 11 participants.
The verdict
NCT01356147, a Phase 4 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
To evaluate the effect of Dornase alfa on preterm and late preterm neonates with ventilator associated pulmonary infections. Dornase alfa has been effective in the treatment of pulmonary infections in patients with cystic fibrosis by aiding mucus clearance. The bacteria causing pulmonary infections in cystic fibrosis patients is similar to those infecting preterm infants. The investigators expect that dornase alfa therapy will improve recovery from ventilator associated pulmonary infections in preterm infants.
Interventions
- DRUG Placebo
- DRUG Dornase alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-05 |
| Est. Completion | 2017-04-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01356147
The ClinicalTrials.gov registry entry for NCT01356147 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01356147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01356147 about?
NCT01356147 is a clinical study titled "Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)". To evaluate the effect of Dornase alfa on preterm and late preterm neonates with ventilator associated pulmonary infections. Dornase alfa has been effective in the treatment of pulmonary infections in patients with cystic fibrosis by aiding mucus clearance. The bacteria causing pulmonary infections ...
What is the current status of trial NCT01356147?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2011-05. Estimated completion is 2017-04-30.
What interventions are being tested in trial NCT01356147?
The interventions under investigation include: Placebo (DRUG), Dornase alfa (DRUG).
Who is sponsoring clinical trial NCT01356147?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.